Time until modification of antiparkinsonian therapy in a group of patients from Colombia
CONCLUSIONS: After five years of treatment, 63.5% of the patients with Parkinson's disease required modifications to their therapy, with a mean time of three years. Male sex, age over 65 years, and receiving initial therapy with amantadine affected the likelihood of switching therapy in these patients in Colombia.PMID:36544370 | DOI:10.33588/rn.7601.2022162 (Source: Revista de Neurologia)
Source: Revista de Neurologia - December 22, 2022 Category: Neurology Authors: A Valencia-V ásquez A Gaviria-Mendoza J D Ayala-Torres F Calvo-Torres J E Machado-Alba Source Type: research
Time until modification of antiparkinsonian therapy in a group of patients from Colombia
CONCLUSIONS: After five years of treatment, 63.5% of the patients with Parkinson's disease required modifications to their therapy, with a mean time of three years. Male sex, age over 65 years, and receiving initial therapy with amantadine affected the likelihood of switching therapy in these patients in Colombia.PMID:36544370 | DOI:10.33588/rn.7601.2022162 (Source: Revista de Neurologia)
Source: Revista de Neurologia - December 22, 2022 Category: Neurology Authors: A Valencia-V ásquez A Gaviria-Mendoza J D Ayala-Torres F Calvo-Torres J E Machado-Alba Source Type: research
Time until modification of antiparkinsonian therapy in a group of patients from Colombia
CONCLUSIONS: After five years of treatment, 63.5% of the patients with Parkinson's disease required modifications to their therapy, with a mean time of three years. Male sex, age over 65 years, and receiving initial therapy with amantadine affected the likelihood of switching therapy in these patients in Colombia.PMID:36544370 | DOI:10.33588/rn.7601.2022162 (Source: Revista de Neurologia)
Source: Revista de Neurologia - December 22, 2022 Category: Neurology Authors: A Valencia-V ásquez A Gaviria-Mendoza J D Ayala-Torres F Calvo-Torres J E Machado-Alba Source Type: research
Time until modification of antiparkinsonian therapy in a group of patients from Colombia
CONCLUSIONS: After five years of treatment, 63.5% of the patients with Parkinson's disease required modifications to their therapy, with a mean time of three years. Male sex, age over 65 years, and receiving initial therapy with amantadine affected the likelihood of switching therapy in these patients in Colombia.PMID:36544370 | DOI:10.33588/rn.7601.2022162 (Source: Revista de Neurologia)
Source: Revista de Neurologia - December 22, 2022 Category: Neurology Authors: A Valencia-V ásquez A Gaviria-Mendoza J D Ayala-Torres F Calvo-Torres J E Machado-Alba Source Type: research
Time until modification of antiparkinsonian therapy in a group of patients from Colombia
CONCLUSIONS: After five years of treatment, 63.5% of the patients with Parkinson's disease required modifications to their therapy, with a mean time of three years. Male sex, age over 65 years, and receiving initial therapy with amantadine affected the likelihood of switching therapy in these patients in Colombia.PMID:36544370 | DOI:10.33588/rn.7601.2022162 (Source: Revista de Neurologia)
Source: Revista de Neurologia - December 22, 2022 Category: Neurology Authors: A Valencia-V ásquez A Gaviria-Mendoza J D Ayala-Torres F Calvo-Torres J E Machado-Alba Source Type: research
Time until modification of antiparkinsonian therapy in a group of patients from Colombia
CONCLUSIONS: After five years of treatment, 63.5% of the patients with Parkinson's disease required modifications to their therapy, with a mean time of three years. Male sex, age over 65 years, and receiving initial therapy with amantadine affected the likelihood of switching therapy in these patients in Colombia.PMID:36544370 | DOI:10.33588/rn.7601.2022162 (Source: Revista de Neurologia)
Source: Revista de Neurologia - December 22, 2022 Category: Neurology Authors: A Valencia-V ásquez A Gaviria-Mendoza J D Ayala-Torres F Calvo-Torres J E Machado-Alba Source Type: research
Time until modification of antiparkinsonian therapy in a group of patients from Colombia
CONCLUSIONS: After five years of treatment, 63.5% of the patients with Parkinson's disease required modifications to their therapy, with a mean time of three years. Male sex, age over 65 years, and receiving initial therapy with amantadine affected the likelihood of switching therapy in these patients in Colombia.PMID:36544370 | DOI:10.33588/rn.7601.2022162 (Source: Revista de Neurologia)
Source: Revista de Neurologia - December 22, 2022 Category: Neurology Authors: A Valencia-V ásquez A Gaviria-Mendoza J D Ayala-Torres F Calvo-Torres J E Machado-Alba Source Type: research
Time until modification of antiparkinsonian therapy in a group of patients from Colombia
CONCLUSIONS: After five years of treatment, 63.5% of the patients with Parkinson's disease required modifications to their therapy, with a mean time of three years. Male sex, age over 65 years, and receiving initial therapy with amantadine affected the likelihood of switching therapy in these patients in Colombia.PMID:36544370 | DOI:10.33588/rn.7601.2022162 (Source: Revista de Neurologia)
Source: Revista de Neurologia - December 22, 2022 Category: Neurology Authors: A Valencia-V ásquez A Gaviria-Mendoza J D Ayala-Torres F Calvo-Torres J E Machado-Alba Source Type: research
Time until modification of antiparkinsonian therapy in a group of patients from Colombia
CONCLUSIONS: After five years of treatment, 63.5% of the patients with Parkinson's disease required modifications to their therapy, with a mean time of three years. Male sex, age over 65 years, and receiving initial therapy with amantadine affected the likelihood of switching therapy in these patients in Colombia.PMID:36544370 | DOI:10.33588/rn.7601.2022162 (Source: Revista de Neurologia)
Source: Revista de Neurologia - December 22, 2022 Category: Neurology Authors: A Valencia-V ásquez A Gaviria-Mendoza J D Ayala-Torres F Calvo-Torres J E Machado-Alba Source Type: research
Time until modification of antiparkinsonian therapy in a group of patients from Colombia
CONCLUSIONS: After five years of treatment, 63.5% of the patients with Parkinson's disease required modifications to their therapy, with a mean time of three years. Male sex, age over 65 years, and receiving initial therapy with amantadine affected the likelihood of switching therapy in these patients in Colombia.PMID:36544370 | DOI:10.33588/rn.7601.2022162 (Source: Revista de Neurologia)
Source: Revista de Neurologia - December 22, 2022 Category: Neurology Authors: A Valencia-V ásquez A Gaviria-Mendoza J D Ayala-Torres F Calvo-Torres J E Machado-Alba Source Type: research
Time until modification of antiparkinsonian therapy in a group of patients from Colombia
CONCLUSIONS: After five years of treatment, 63.5% of the patients with Parkinson's disease required modifications to their therapy, with a mean time of three years. Male sex, age over 65 years, and receiving initial therapy with amantadine affected the likelihood of switching therapy in these patients in Colombia.PMID:36544370 | DOI:10.33588/rn.7601.2022162 (Source: Revista de Neurologia)
Source: Revista de Neurologia - December 22, 2022 Category: Neurology Authors: A Valencia-V ásquez A Gaviria-Mendoza J D Ayala-Torres F Calvo-Torres J E Machado-Alba Source Type: research
Time until modification of antiparkinsonian therapy in a group of patients from Colombia
CONCLUSIONS: After five years of treatment, 63.5% of the patients with Parkinson's disease required modifications to their therapy, with a mean time of three years. Male sex, age over 65 years, and receiving initial therapy with amantadine affected the likelihood of switching therapy in these patients in Colombia.PMID:36544370 | DOI:10.33588/rn.7601.2022162 (Source: Revista de Neurologia)
Source: Revista de Neurologia - December 22, 2022 Category: Neurology Authors: A Valencia-V ásquez A Gaviria-Mendoza J D Ayala-Torres F Calvo-Torres J E Machado-Alba Source Type: research
Neurotensin-Binding Immunoglobulin G in Patients with Parkinson ’s Disease
Discussion: The study revealed that NTS-binding IgG occur naturally in humans and that PD patients display their low plasma levels accentuated by disease severity. The functional significance of this finding and its relevance to the pathophysiology of PD, including putative link to gut microbiota, remain to be studied.Neuroimmunomodulation (Source: Neuroimmunomodulation)
Source: Neuroimmunomodulation - December 14, 2022 Category: Allergy & Immunology Source Type: research
Neurotensin-Binding Immunoglobulin G in Patients with Parkinson ’s Disease
Discussion: The study revealed that NTS-binding IgG occur naturally in humans and that PD patients display their low plasma levels accentuated by disease severity. The functional significance of this finding and its relevance to the pathophysiology of PD, including putative link to gut microbiota, remain to be studied.Neuroimmunomodulation 2023;30:15 –27 (Source: Neuroimmunomodulation)
Source: Neuroimmunomodulation - December 14, 2022 Category: Allergy & Immunology Source Type: research
Transcranial direct current stimulation combined with amantadine in repetitive mild traumatic brain injury in rats
Balance and memory deficits are common in patients with repetitive mild traumatic brain injury (mTBI). (Source: BMC Neuroscience)
Source: BMC Neuroscience - December 11, 2022 Category: Neuroscience Authors: Soo Jeong Han, Gahee Park and Jee Hyun Suh Tags: Research Source Type: research
